On Monday afternoon 3/3/2014, Synta Pharma issued a press release stating that CEO and co-founder Safi Bahcall had resigned effective immediately. As you may know, I have been covering SNTA and the development of their oncology drug candidate, the HSP90 inhibitor ganetespib, extensively. As such I thought I would offer a quick reaction to the news, and offer my answer to the question posed this morning by TheStreet's Adam Feuerstein "Will the company continue with the ongoing phase III study of ganetespib in non-small cell lung cancer? Or, is Bahcall's resignation the first step in a major overhaul of the company?"
For the moment, this will be the final installment of the BiotechDueDiligence AACR Annual Meeting preview..thanks for sticking with us. As always, see below for another collection of presentations from biotech companies covered on the website.
Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Preview Part 4 (ASTX, ARQL, BPAX)
Preview Part 5 (TKMR, EXEL, PCYC, IMMU, VRTX)
Preview Part 6 (CRIS INFI ISIS CLDX LGND PCYC)
Cleaning out my notes, so excuse the tardiness, but posting for context. Get more background of Synta Pharma $SNTA and ganetespib, or learn about the HSP90 inhibitor class generally.
Synta Pharma will have numerous presentations at the AACR cancer research meeting this week. See below for a couple abstracts on their elesclomol program.
Visit HSP90 Central for a number of abstracts related to their HSP90 inhibitor ganetespib (STA-9090)
You've probably read about the HSP90 inhibitor programs from companies like SNTA, ASTX, INFI, and MYRX here at BiotechDueDiligence. If you're interested in these promising but often troubled candidates, you'll want to check out the sister site dedicated to this class of drugs - HSP90 Inhibitors Central.
Most recent updates over on that site are related to AUY922 and HSP990, being developed by Novartis $NVS and Vernalis LSE:$VER.
2012 is a big year for clinical data from HSP90 inhibitors, and you'll continue to find more updates on both of the sites, as well as detailed analysis for Chimera Research subscribers as we go through the year.